JP2001503266A - 環状に並べ替えたエリスロポイエチン受容体アゴニスト - Google Patents

環状に並べ替えたエリスロポイエチン受容体アゴニスト

Info

Publication number
JP2001503266A
JP2001503266A JP52052898A JP52052898A JP2001503266A JP 2001503266 A JP2001503266 A JP 2001503266A JP 52052898 A JP52052898 A JP 52052898A JP 52052898 A JP52052898 A JP 52052898A JP 2001503266 A JP2001503266 A JP 2001503266A
Authority
JP
Japan
Prior art keywords
seq
receptor agonist
cells
epo receptor
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP52052898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503266A5 (enExample
Inventor
マックワーター，チャールズ，エイ．
フェン，イイキン
サマーズ，ニーナ
Original Assignee
ジー．ディー．サール アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジー．ディー．サール アンド カンパニー filed Critical ジー．ディー．サール アンド カンパニー
Publication of JP2001503266A publication Critical patent/JP2001503266A/ja
Publication of JP2001503266A5 publication Critical patent/JP2001503266A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP52052898A 1996-10-25 1997-10-23 環状に並べ替えたエリスロポイエチン受容体アゴニスト Abandoned JP2001503266A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3404496P 1996-10-25 1996-10-25
US60/034,044 1996-10-25
PCT/US1997/018703 WO1998018926A1 (en) 1996-10-25 1997-10-23 Circularly permuted erythropoietin receptor agonists

Publications (2)

Publication Number Publication Date
JP2001503266A true JP2001503266A (ja) 2001-03-13
JP2001503266A5 JP2001503266A5 (enExample) 2005-05-12

Family

ID=21873960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52052898A Abandoned JP2001503266A (ja) 1996-10-25 1997-10-23 環状に並べ替えたエリスロポイエチン受容体アゴニスト

Country Status (13)

Country Link
US (1) US20060172932A1 (enExample)
EP (1) EP0939816A1 (enExample)
JP (1) JP2001503266A (enExample)
KR (1) KR20000052807A (enExample)
CN (1) CN1234073A (enExample)
AU (1) AU721196B2 (enExample)
BR (1) BR9712675A (enExample)
CA (1) CA2268001A1 (enExample)
CZ (1) CZ130199A3 (enExample)
NO (1) NO991906L (enExample)
NZ (1) NZ334546A (enExample)
PL (1) PL189756B1 (enExample)
WO (1) WO1998018926A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527980A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
ATE384785T1 (de) 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
NZ542585A (en) 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
CA2621705A1 (en) * 2005-11-24 2007-05-31 Laboratoires Serono S.A. Erythropoietin polypeptides and uses thereof
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI584815B (zh) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
MX2009008510A (es) 2007-02-09 2010-01-15 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
CN110144010B9 (zh) * 2018-02-14 2021-01-05 上海洛启生物医药技术有限公司 阻断型pd-l1驼源单域抗体及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH05502463A (ja) * 1990-09-28 1993-04-28 オーソ・フアーマシユーチカル・コーポレーシヨン ハイブリツド成長因子
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527980A (ja) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子

Also Published As

Publication number Publication date
WO1998018926A1 (en) 1998-05-07
CN1234073A (zh) 1999-11-03
CA2268001A1 (en) 1998-05-07
AU5081098A (en) 1998-05-22
PL332960A1 (en) 1999-10-25
AU721196B2 (en) 2000-06-29
CZ130199A3 (cs) 1999-07-14
BR9712675A (pt) 1999-10-19
NZ334546A (en) 2000-12-22
PL189756B1 (pl) 2005-09-30
KR20000052807A (ko) 2000-08-25
NO991906D0 (no) 1999-04-21
US20060172932A1 (en) 2006-08-03
EP0939816A1 (en) 1999-09-08
NO991906L (no) 1999-04-21

Similar Documents

Publication Publication Date Title
AU721196B2 (en) Circularly permuted erythropoietin receptor agonists
AU734594B2 (en) Circularly permuted polypeptides as novel stem cell factor receptor agonists
AU2018372167A1 (en) Partial agonists of interleukin-2
US6660257B1 (en) Circular permuteins of flt3 ligand
JP2013512672A (ja) ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
JPH09508524A (ja) Ｉｌ−３変種造血融合蛋白
KR100456212B1 (ko) 다기능성조혈수용체아고니스트
AU717733B2 (en) Novel G-CSF receptor agonists
JP2001504689A (ja) 多機能性キメラ造血レセプターアゴニスト
WO1997012985A9 (en) Multi-functional hematopoietic receptor agonists
US6358505B1 (en) G-CSF receptor agonists
US20070081979A1 (en) Multi-functional chimeric hematopoietic receptor agonists
AU722759B2 (en) Novel C-MPL receptor agonists
AU703627B2 (en) Interleuken-3 (IL-3) receptor agonists
JP2002515729A (ja) 新規ｇ−ｃｓｆ受容体アゴニスト
MXPA99003874A (es) Agonistas del receptor de eritropoyetina circularmente permutados
MXPA99003875A (en) NOVEL flt-3 RECEPTOR AGONISTS
CZ346799A3 (cs) Chimérické proteiny jako flt3 ligandy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040820

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20070219